Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$734M |
| 2 |
Adobe
ADBE
|
+$488M |
| 3 |
Merck
MRK
|
+$443M |
| 4 |
Tesla
TSLA
|
+$366M |
| 5 |
AGN
Allergan plc
AGN
|
+$315M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$682M |
| 2 |
Perrigo
PRGO
|
+$585M |
| 3 |
Gilead Sciences
GILD
|
+$556M |
| 4 |
EMC
EMC CORPORATION
EMC
|
+$432M |
| 5 |
Morgan Stanley
MS
|
+$401M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.94% |
| 2 | Consumer Discretionary | 14.99% |
| 3 | Communication Services | 11.27% |
| 4 | Technology | 9.94% |
| 5 | Financials | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
701
USA Compression Partners
USAC
$3.69B
| $204K | ﹤0.01% |
+7,608
| New | +$186K |
|
702
Cheniere Energy
CQP
$30.5B
| $202K | ﹤0.01% |
+7,049
| New | +$205K |
|
703
Agnico Eagle Mines
AEM
$72.2B
| – | – |
-16,560
| Closed | -$438K |
|
704
American Eagle Outfitters
AEO
$2.94B
| – | – |
-873,876
| Closed | -$12.2M |
|
|
AMRN
705
Amarin Corp
AMRN
$297M
| – | – |
-256,171
| Closed | -$32.4M |
|
706
Angi Inc
ANGI
$247M
| – | – |
-3,722
| Closed | -$837K |
|
707
Broadcom
AVGO
$1.76T
| – | – |
-7,904,030
| Closed | -$34.1M |
|
708
Conagra Brands
CAG
$7.42B
| – | – |
-114,194
| Closed | -$2.7M |
|
709
C.H. Robinson
CHRW
$20.5B
| – | – |
-1,288,824
| Closed | -$76.8M |
|
710
Charles River Laboratories
CRL
$11.3B
| – | – |
-6,037
| Closed | -$279K |
|
711
Danaher
DHR
$138B
| – | – |
-16,449
| Closed | -$766K |
|
712
Fastenal
FAST
$54.8B
| – | – |
-999,736
| Closed | -$12.6M |
|
713
Fortress Biotech
FBIO
$111M
| – | – |
-109,660
| Closed | -$11.5M |
|
714
Green Dot
GDOT
$750M
| – | – |
-12,109
| Closed | -$319K |
|
715
Gen Digital
GEN
$16.5B
| – | – |
-31,235
| Closed | -$773K |
|
716
HUB Group
HUBG
$2.92B
| – | – |
-1,680,038
| Closed | -$33M |
|
717
IBM
IBM
$213B
| – | – |
-13,816
| Closed | -$2.45M |
|
718
PUT
iShares Russell 2000 ETF
IWM
$79.1B
| – | – |
-2,000,000
| Closed | -$213M |
|
719
Lockheed Martin
LMT
$131B
| – | – |
-25,082
| Closed | -$3.2M |
|
720
LyondellBasell Industries
LYB
$19.5B
| – | – |
-15,831
| Closed | -$1.16M |
|
721
Neurocrine Biosciences
NBIX
$18.2B
| – | – |
-1,642,465
| Closed | -$18.6M |
|
722
Oracle
ORCL
$339B
| – | – |
-100,878
| Closed | -$3.35M |
|
723
Petrobras
PBR
$120B
| – | – |
-88,061
| Closed | -$1.36M |
|
724
PG&E
PCG
$39B
| – | – |
-661,002
| Closed | -$27M |
|
725
Precigen
PGEN
$1.94B
| – | – |
-235,425
| Closed | -$5.33M |
|
Similar funds
Jennison Associates's Q4 2013 Portfolio in Review
As of Q4 2013, Jennison Associates held 759 positions worth $102B, up 6.9% from $95.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q4 2013 filing shows 79 new, 184 increased, 411 reduced and 54 closed positions. Its largest new stake was Allergan plc: 2,016,619 shares worth $339M. The largest sale was UnitedHealth, an estimated $682M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q4 2013 buy was Allergan plc: 2,016,619 shares worth $339M.
- Jennison Associates added most to Bristol-Myers Squibb in Q4 2013, an estimated $734M increase.
- Jennison Associates's biggest Q4 2013 reduction was UnitedHealth, cutting an estimated $682M.
- Jennison Associates fully exited Perrigo in Q4 2013, selling an estimated $585M.
- Jennison Associates's ten largest holdings make up 20% of its $102B portfolio in Q4 2013.
- Jennison Associates opened 79 new positions and closed 54 in Q4 2013.
- Jennison Associates's portfolio value rose 6.9% quarter-over-quarter to $102B.
Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.